Challenges in RCTs solved with joint models?

Floor van Oudenhoven

Nutricia Research, Erasmus Medical Centre

Joint work with Prof. Dr. Dimitris Rizopoulos and Dr. Sophie Swinkels

23 November 2018

Overview

Randomized controlled trial



- A type of **clinical trial**
- Compares two (or more) groups:
  - Treatment vs. placebo
  - Or new treatment vs. existing treatment
  - Patients are randomly assigned to the groups
  - Goal: to assess the **treatment effect**

Joint models

- Joint models combine longitudinal and survival data
- Methods for a separate analysis are well established



Joint models



Joint models

- **Mixed effects model**

$$\begin{aligned} y_i(t) &= m_i(t) + \epsilon_i(t) \\ &= x_i^\top(t)\beta + z_i^\top(t)b_i + \epsilon_i(t) \end{aligned}$$

- where $m_i(t)$ is the *true* and *unobserved* longitudinal outcome, with history $\mathcal{M}_i(t) = \{m_i(s), 0 \leq s < s\}$

Joint models

- **Mixed effects model**

$$\begin{aligned} y_i(t) &= m_i(t) + \epsilon_i(t) \\ &= x_i^\top(t)\beta + z_i^\top(t)b_i + \epsilon_i(t) \end{aligned}$$

- where $m_i(t)$ is the *true* and *unobserved* longitudinal outcome, with history $\mathcal{M}_i(t) = \{m_i(s), 0 \leq s < s\}$

- **Survival model (Cox model)**

$$h_i(t|\mathcal{M}_i(t), w_i) = h_0(t)\exp\{\gamma^\top w_i + \alpha m_i(t)\}$$

- where α quantifies the *association* between the longitudinal outcome and the risk of an event

Overall treatment effect in a joint model

- Interest in the process of how a treatment affects a survival outcome (e.g., Alzheimer studies)



- The treatment effect is a combination of:
  - The (indirect) treatment effect in the longitudinal process
  - The (direct) treatment effect in the survival process

Overview

Overall treatment effect in a joint model

- **Mixed effects model**

$$\begin{aligned} y_i(t) &= m_i(t) + \epsilon_i(t) \\ &= \beta_0 + \beta_1 t + \beta_2 (t \times trt_i) + b_{i0} + b_{i1} t + \epsilon_i(t) \end{aligned}$$

- **Survival model**

$$h_i(t) = h_0(t) \exp\{\gamma trt_i + \alpha m_i(t)\}$$

- What is the **overall treatment effect**?

Overall treatment effect in a joint model

- **Mixed effects model**

$$\begin{aligned} y_i(t) &= m_i(t) + \epsilon_i(t) \\ &= \beta_0 + \beta_1 t + \boldsymbol{\beta_2}(t \times trt_i) + b_{i0} + b_{i1} t + \epsilon_i(t) \end{aligned}$$

- **Survival model**

$$h_i(t) = h_0(t) \exp\{\boldsymbol{\gamma} trt_i + \boldsymbol{\alpha} m_i(t)\}$$

- What is the **overall treatment effect**?
- First guess: $\boxed{\gamma + \alpha\beta_2 t}$

Overall treatment effect in a joint model



Overall treatment effect in a joint model

- Treatment effect is the hazard ratio between patient i (treatment) and patient i' (control)

$$\frac{h_i(t)}{h_{i'}(t)} = \frac{\exp[\gamma + \alpha\{\cancel{\beta_0} + \cancel{\beta_1 t} + \beta_2(t \times trt_i) + b_{i0} + b_{i1}t\}]}{\exp[\alpha\{\cancel{\beta_0} + \cancel{\beta_1 t} + b_{i'0} + b_{i'1}t\}]}$$

Overall treatment effect in a joint model

- Treatment effect is the hazard ratio between patient i (treatment) and patient i' (control)

$$\frac{h_i(t)}{h_{i'}(t)} = \frac{\exp[\gamma + \alpha\{\cancel{\beta_0} + \cancel{\beta_1 t} + \beta_2(t \times trt_i) + b_{i0} + b_{i1}t\}]}{\exp[\alpha\{\cancel{\beta_0} + \cancel{\beta_1 t} + b_{i'0} + b_{i'1}t\}]}$$

$$= \exp\{\gamma + \alpha\beta_2 t + \alpha(b_{i0} + b_{i1}t - b_{i'0} + b_{i'1}t)\}$$

- Patient i and i' are two different patients, i.e., $b_i \neq b_{i'}$

Overall treatment effect in a joint model

- exp() is a non-linear link function

$$E[g(X)] \neq g(E[X])$$

$$E_b[g(\gamma + \alpha\beta_2 t + \alpha(Zb_i - Zb_{i'})] \neq g(E_b[\gamma + \alpha\beta_2 t + \alpha(Zb_i - Zb_{i'})])$$

- Average treatment effect $\neq$ the treatment effect for average subject
- The overall treatment effect $\boxed{\gamma + \alpha\beta_2 t}$ $\rightarrow$ **Subject-Specific (SS)** interpretation

Marginal and Subject-Specific effects

- Marginal and SS effects differ in **value** and **interpretation**
- **SS effects**
  - Conditional on the random effects
  - Individual-based inference (growth studies, personalized medicine)

  Marginal effects
  - Population averaged effects
  - Population-based inference (testing new drugs for efficacy)

Marginal versus Subject-Specific effects

- **SS** overall treatment effect $\rightarrow$ effect of receiving the treatment instead of placebo for a specific patient, i.e., it is conditional on her random effects
- **Marginal** overall treatment effect $\rightarrow$ average treatment effect in population $\rightarrow$ currently not available

Marginal versus Subject-Specific effects

- Similar situation: Clustered longitudinal data with a binary outcome
  - SS approaches: Generalized Linear Mixed Models (GLMMs)
    - Mixed models are a special case of GLMMs
  - Marginal approaches: GEE, Marginalized Multilevel Model
  - [Hedeker, 2017] proposed a method for the marginalization of regression parameters of GLMM

Hedeker et al. (2017). A note on marginalization of regression parameters from mixed models of binary outcomes. Biometrics

Marginal versus Subject-Specific effects



The average probability $\neq$ probability for the average patient

Overview

Proposed method

- Goal: marginal overall treatment effect $\boxed{\gamma^M + \alpha^M \beta_2^M t}$
- Remember

$$h_i(t) = h_0(t) \exp\{\gamma^\top w_i + \alpha \underbrace{(x_i^\top(t)\beta + z_i^\top(t) b_i)}_{m_i(t)}\}$$

Proposed method

- $$\log HR_i^M = w_i \gamma^M + x_i \alpha^M \beta^M = \tilde{X}_i \theta^M$$
- Multiplying both sides by $(\tilde{X}^\top \tilde{X})^{-1} \tilde{X}^\top$:

$$\theta^M = \left(\sum_{i=1}^{N+n} \tilde{x}_i{}^\top \tilde{x}_i \right)^{-1} \left(\sum_{i=1}^{N+n} \tilde{x}_i{}^\top \log HR_i^M \right)$$

- Gives us: $\boxed{\gamma^M + \alpha^M \beta_2^M t}$

Results proposed method

- As an example we use the available Prothro dataset
- 488 patients with liver cirrhosis
- Longitudinal outcome: prothrombin
- Survival outcome: patient survival
- Goal:
  - Compare the marginal and SS overall treatment effect on patient survival
  - Compare the marginal and SS hazard ratios ($\log HR_i^M$ vs. $\log HR_i^{SS}$)

Results proposed method



A) Hazard ratios versus the baseline hazard
B) Overall treatment effect

Simulation study

- We investigated the effect of two parameters:
  - The association parameter α
  - The variance of the random slope $\Sigma_{b_1^2}$

Simulation study



1) $\alpha =$ low, $\Sigma_{b_1^2} =$ low
2) $\alpha =$ low, $\Sigma_{b_1^2} =$ high
3) $\alpha =$ high, $\Sigma_{b_1^2} =$ low
4) $\alpha =$ high, $\Sigma_{b_1^2} =$ high

Conclusion

- The **overall treatment effect** in joint model is a combination of the treatment effect in the longitudinal and survival model
- The obtained treatment effect has a **Subject-Specific** interpretation
- Whether Subject-Specific or marginal effects are desirable depends on the target of inference
- A **marginal** overall treatment effect can be obtained using the proposed method

References

Hedeker et al. (2017)

A note on marginalization of regression parameters from mixed models of binary outcomes.

Biometrics 74(1), 354 – 361.

Rizopoulos (2012)

Joint models for longitudinal and time-to-event data: With applications in R.

Chapman and Hall/CRC.

Thank you!